Novel treatment approaches are needed to overcome innate and acquired mechanisms of
resistance to current anticancer therapies in cancer cells and the tumour immune …

AXL is a member of the TAM (TYRO3, AXL, and MERTK) receptor tyrosine kinases family
(RTKs), and its abnormal expression has been linked to clinicopathological features and …

In this work, a sensitive signal-on electrochemiluminescence biosensor using liposome-
encapsuled 1, 1, 2, 2-tetra (4-carboxylphenyl) ethylene (TPE) as a promising aggregation …

AXL kinase is heavily involved in tumorigenesis, metastasis, and drug resistance of many
cancers, and several AXL inhibitors are in clinical investigations. Recent studies …

Simple Summary HER2-positive metastatic breast cancer remains a nearly incurable
disease. In this sense, new treatments have been developed in recent years. On the one …

HER2 is a driver in solid tumors, mainly breast, oesophageal and gastric cancer, through
activation of oncogenic signaling pathways such as PI3K or MAPK. HER2 overexpression …

Early cancer recurrence, driven by resistance to therapeutics, is a major obstacle to
overcome poor survival in triple negative breast cancer (TNBC). Recently, overexpression of …

Antibody-drug conjugates (ADCs) are the most potent active tumor-targeting agents used
clinically. However, the preparation of ADCs with high drug-to-antibody ratios (DARs) …

Anti‐HER2 (human epidermal growth factor receptor 2) therapies significantly increase the
overall survival of patients with HER2‐positive breast cancer. Unfortunately, a large fraction …

Despite incredible progress in cancer treatment, therapy resistance remains the leading
limiting factor for long-term survival. During drug treatment, several genes are …